2220 GMT - Ord Minnett is confident about its buy call on Regis Healthcare ahead of key reforms to accommodation funding on Nov. 1. It expects these reforms to be a material driver of Regis's medium-term earnings. Central to this is room pricing, known to investors as RAD, says analyst Tom Godfrey. "We note that the company's latest advertised prices have increased 19% since December," to now stand at A$638,000, says Ord Minnett. This is well ahead of its estimates. Ord Minnett says this can raise Regis's RAD funding to A$2.2 billion, from A$1.7 billion. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
June 15, 2025 18:20 ET (22:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。